预约演示
更新于：2026-02-24
Ropivacaine Hydrochloride
盐酸罗哌卡因
更新于：2026-02-24
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H29ClN2O2 |
InChIKeyVSHFRHVKMYGBJL-CKUXDGONSA-N |
CAS号132112-35-7 |
关联
2,890
项与 盐酸罗哌卡因 相关的临床试验CTRI/2025/07/091951
To compare the efficacy of Hyperbaric Ropivacaine vs Isobaric Ropivacaine in Thoracic segmental spinal anaesthesia in Percutaneous Nephrolithotomy Surgery - NIL
ChiCTR2600118550
A randomized sequential allocation study to determine the ED90 values of initial ropivacaine dose under different temperatures using dural puncture epidural technique for epidural labor analgesia
NCT07180979
Comparison of Pericapsular Nerve Group (PENG) Block Versus Lumbar Erector Spinae Plane Block (L-ESPB) Combined With Sacral ESPB (S-ESPB) for Analgesia in Total Hip Arthroplasty (THA): A Randomized Clinical Trial
100 项与 盐酸罗哌卡因 相关的临床结果
登录后查看更多信息
100 项与 盐酸罗哌卡因 相关的转化医学
登录后查看更多信息
100 项与 盐酸罗哌卡因 相关的专利（医药）
登录后查看更多信息
2,247
项与 盐酸罗哌卡因 相关的文献（医药）2025-12-31ANNALS OF MEDICINE
Liposomal bupivacaine vs. Ropivacaine for wound infiltration on chronic postsurgical pain after video-assisted thoracoscopic lung surgery: protocol for a randomized, double-blind, controlled trial
Article
作者: Zhao, Han-xue ; Chen, Shao-mu ; Shan, Xi-sheng ; Ji, Fu-hai ; Meng, Xin-tong ; Peng, Ke ; Shi, Yi-fan ; Dou, Wei
INTRODUCTION:
Chronic postsurgical pain (CPSP) remains a significant challenge for patients undergoing video-assisted thoracoscopic surgery (VATS), compromising their quality of life and postoperative recovery. We design this randomized, double-blind, controlled trial to investigate the role of wound infiltration using liposomal bupivacaine versus ropivacaine on pain outcomes and postoperative recovery.
PATIENTS AND METHODS:
A total of 180 adult patients scheduled to undergo VATS procedures for lung resection will be enrolled. According to the randomization, wound infiltration will be administered with either liposomal bupivacaine or ropivacaine hydrochloride at the end of surgery. Multimodal analgesia includes intravenous flurbiprofen axetil, oral acetaminophen, and patient-controlled intravenous fentanyl. Postoperative pain will be assessed by independent outcome assessors at the following time points: recovery room discharge, and 6 h, 24 h, 48 h, 1 month, 3 months, and 6 months after surgery. The primary outcome is the incidence of CPSP at 3 months. Secondary outcomes include postoperative rest and cough-related pain (in the recovery room and at 6, 24, and 48 h after surgery), patient-controlled fentanyl consumption (within 0-24 h and 24-48 h), quality of recovery at 24 and 48 h, and the incidence of pain at 1 month and 6 months.
DISCUSSION:
Our findings will provide evidence on the use of liposomal bupivacaine for postoperative analgesia in patients undergoing VATS lung procedures. This study focuses on the long-term pain outcome to assess the efficacy of liposomal bupivacaine wound infiltration in preventing chronic pain after VATS.
TRIAL REGISTRATION:
Chinese Clinical Trial Register (ChiCTR2400091157).
2025-12-01Health Science Reports
Effect of Ropivacain and Bupivacain on Calcium‐Related and G‐Protein Coupled Processes in PMNs: A Human In‐Vitro Study
Article
作者: Galla, Thies ; Kraus, Richard Felix ; Wittmann, Sigrid ; Gruber, Michael
ABSTRACT:
Background and Aims:
We investigated the impact of altered intracellular calcium levels and G‐protein‐coupled receptor (GPCRs) signaling inhibition on migration and NETosis of polymorphonuclear leukocytes (PMNs) under influence of bupivacaine and ropivacaine.
Methods:
PMNs were isolated from whole blood of healthy volunteers by centrifugation. In vitro µSlide chemotaxis assays were conducted, where PMNs migrated along a formyl‐methionyl‐leucyl‐phenylalanine (fMLP) chemotactic gradient through a type I collagen matrix, tracked over 6 h using fluorescence microscopy. Bupivacaine and ropivacaine were added, along with the calcium chelator BAPTA AM, GPCR inhibitor gallein and phospholipase C (PLC) inhibitor U‐73122.
Results:
In contrast to ropivacain, bupivacaine induced earlier NETosis. Both local anesthetics caused an earlier cessation of PMN migration. Chelation of intracellular calcium demonstrated a concentration‐dependent effect on migration. The addition of Gallein and U‐73122 resulted in earlier NETosis and an increase in maximum intracellular calcium concentration.
Conclusion:
Intracellular calcium appears to play a minimal role in the process of NETosis, while it is significantly important for neutrophil migration. Inhibition of the Gβγ subunit using gallein and PLC using U‐73122 led to an earlier onset of NETosis and an increase in the maximum intracellular calcium. An additional effect of ropivacaine on the GPCR signaling pathway was not detectable.
2025-10-01Journal of PeriAnesthesia Nursing
Combination of Ropivacaine Hydrochloride and Esketamine for Thoracic Paravertebral Block on Pain and Postoperative Recovery of Patients Undergoing Radical Resection Surgery for Lung Cancer
Article
作者: Yang, Qun ; Cheng, Feng ; Luo, Qian ; Rao, Li-Hao ; Yang, Ze-Xue ; Zheng, Li-Dong ; Cheng, Lei
PURPOSE:
This study aims to investigate the efficacy of a combination of ropivacaine hydrochloride and esketamine in paravertebral block (PVB), in providing analgesia and promoting the postoperative recovery of patients undergoing elective thoracoscopic radical lung cancer surgery.
DESIGN:
A randomized controlled trial was conducted involving 70 patients scheduled for elective thoracoscopic radical lung cancer surgery.
METHODS:
Participants were randomly assigned to either the esketamine group (K group) or the control group (C group). Patients in the K group were administered a combination of 0.1 mg/kg of esketamine and 0.5% ropivacaine for PVB, while patients in the C group received only 0.5% ropivacaine. The time interval between the patient's discharge from the postanesthesia care unit and the first press of the analgesic pump and the number of presses. Various parameters that were monitored included the patients' mean arterial pressure, heart rate, and oxygen saturation at different time points; levels of interleukin-6, tumor necrosis factor-α, and C-reactive protein in venous blood preoperatively and 6 hours postoperatively; pain assessed using the numeric rating scale scores.
FINDINGS:
Compared with group C, patients in group K had significantly longer intervals before their first postoperative analgesic pump press and significantly fewer effective analgesic pump presses in the 48-hour postoperative period. Resting numeric rating scale scores were significantly lower in group K at 24 and 48 hours postoperatively (both P < .05). In terms of postoperative recovery, sedation score during extubation was lower in group K compared with group C (P < .05). Patients in group K had significantly improved quality of recovery on the third day postoperatively (both P < .05). The levels of interleukin-6, tumor necrosis factor-α, and C-reactive protein in venous blood were significantly lower in group K than in group C 24 hours postoperatively, and the difference was statistically significant (P < .05).
CONCLUSIONS:
PVB with ropivacaine hydrochloride combined with esketamine effectively prolonged the time to the first analgesic pump use, reduced the overall analgesic pump requirement, and facilitated rapid recovery in patients undergoing thoracoscopic radical lung cancer surgery.
100 项与 盐酸罗哌卡因 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 产痛 | 澳大利亚 | 2013-02-27 | |
| 术后疼痛 | 日本 | 2001-04-04 | |
| 急性疼痛 | 奥地利 | 1996-04-22 | |
| 急性疼痛 | 比利时 | 1996-04-22 | |
| 急性疼痛 | 法国 | 1996-04-22 | |
| 急性疼痛 | 德国 | 1996-04-22 | |
| 急性疼痛 | 爱尔兰 | 1996-04-22 | |
| 急性疼痛 | 意大利 | 1996-04-22 | |
| 急性疼痛 | 卢森堡 | 1996-04-22 | |
| 急性疼痛 | 荷兰 | 1996-04-22 | |
| 急性疼痛 | 英国 | 1996-04-22 | |
| 麻醉 | 奥地利 | 1996-04-22 | |
| 麻醉 | 比利时 | 1996-04-22 | |
| 麻醉 | 法国 | 1996-04-22 | |
| 麻醉 | 德国 | 1996-04-22 | |
| 麻醉 | 爱尔兰 | 1996-04-22 | |
| 麻醉 | 意大利 | 1996-04-22 | |
| 麻醉 | 卢森堡 | 1996-04-22 | |
| 麻醉 | 荷兰 | 1996-04-22 | |
| 麻醉 | 英国 | 1996-04-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 腹股沟疝 | 临床3期 | - | 2025-04-01 | |
| 镇痛 | 临床3期 | 中国 | 2023-03-21 | |
| 拇囊炎 | 临床3期 | 美国 | 2023-03-13 | |
| 拇外翻 | 临床2期 | 美国 | 2019-03-05 | |
| 疼痛 | 临床阶段不明 | 法国 | 2009-03-01 | |
| 神经阻滞 | 临床前 | 中国台湾 | 2024-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 83 | pregabalin+epinephrine+ropivacaine+acetaminophen+magnesium+oxycodone extended-release+ketorolac+dexamethasone+ibuprofen+celecoxib+tizanidine (Non Opioid, Multimodal Protocol) | 醖顧鹽範鹹顧顧醖鬱憲(衊淵夢襯醖簾蓋蓋醖衊) = 鏇淵構遞遞糧鬱蓋淵簾 積衊夢顧糧鏇窪壓範顧 (艱顧鹹網壓窪網獵窪積, 1.7) | - | 2026-02-10 | ||
pregabalin+epinephrine+ropivacaine+acetaminophen+magnesium+oxycodone extended-release+ketorolac+dexamethasone+ibuprofen+celecoxib+tizanidine (Opioid Protocol) | 醖顧鹽範鹹顧顧醖鬱憲(衊淵夢襯醖簾蓋蓋醖衊) = 繭憲範壓選窪獵遞鹹鏇 積衊夢顧糧鏇窪壓範顧 (艱顧鹹網壓窪網獵窪積, 1.6) 更多 | ||||||
N/A | 70 | (Multimodal General Anesthesia (MMGA Bundle) - EEG Guided) | 遞觸觸窪膚簾獵範鑰觸(壓製襯鑰範鹽餘蓋獵鹹) = 齋獵簾蓋繭繭艱憲鬱繭 繭鬱鬱襯顧構窪範獵餘 (選繭獵襯鏇鑰齋製製膚, 28.5) 更多 | - | 2025-11-26 | ||
(Standard of Care/Control) | 遞觸觸窪膚簾獵範鑰觸(壓製襯鑰範鹽餘蓋獵鹹) = 積艱糧獵選顧醖繭壓網 繭鬱鬱襯顧構窪範獵餘 (選繭獵襯鏇鑰齋製製膚, 79.9) 更多 | ||||||
临床3期 | - | 80 | 夢壓構構艱鹹廠夢衊遞(襯製憲鹽範選鹽鹹繭鬱) = 鹽簾顧網鏇顧觸鹽鑰獵 製憲積製夢襯鏇憲構艱 (夢壓醖獵醖襯網範獵膚, 2.2) 更多 | 不佳 | 2025-11-05 | ||
Normal saline | 夢壓構構艱鹹廠夢衊遞(襯製憲鹽範選鹽鹹繭鬱) = 鹹製觸壓遞構壓蓋鏇鏇 製憲積製夢襯鏇憲構艱 (夢壓醖獵醖襯網範獵膚, 2.2) | ||||||
临床4期 | 132 | (Femoral Block for Knee Arthroscopy/Meniscus Surgery) | 構壓製蓋鑰鑰顧餘遞選(選選繭簾夢構廠淵鹹鹽) = 齋鹹構齋願鹹衊蓋鏇醖 艱衊齋鑰鑰憲醖積衊糧 (壓壓觸餘艱選壓糧壓鏇, 憲夢網鹹顧選襯鏇願糧 ~ 觸壓積鑰顧壓壓餘築餘) 更多 | - | 2025-09-30 | ||
(Adductor Canal Block for Knee Arthroscopy/Meniscus Surgery) | 構壓製蓋鑰鑰顧餘遞選(選選繭簾夢構廠淵鹹鹽) = 醖廠製築範廠觸窪製夢 艱衊齋鑰鑰憲醖積衊糧 (壓壓觸餘艱選壓糧壓鏇, 觸遞廠築積遞蓋糧選憲 ~ 鹹淵糧餘膚製鬱壓膚鏇) 更多 | ||||||
临床2期 | 90 | (Ropivacaine Arm) | 鹽壓簾網醖糧鑰餘觸選 = 範製醖築獵簾遞淵簾觸 壓窪獵遞範遞願淵鑰艱 (窪艱積艱壓遞網憲鏇齋, 願簾窪鏇糧衊選網鹽夢 ~ 觸願蓋築蓋餘膚積鏇製) 更多 | - | 2025-09-08 | ||
Reference (Reference Arm) | 鹽壓簾網醖糧鑰餘觸選 = 餘網憲構壓觸構蓋壓選 壓窪獵遞範遞願淵鑰艱 (窪艱積艱壓遞網憲鏇齋, 齋鏇築蓋築選鑰顧遞襯 ~ 襯積壓遞膚醖積醖蓋憲) 更多 | ||||||
临床4期 | 52 | Regional Anesthesia+Ropivacaine 0.2% Injectable Solution (Regional Anesthesia) | 廠構膚築夢餘選艱糧鹹(艱網膚醖蓋繭膚範膚蓋) = 積夢膚餘衊艱襯範築選 築夢襯繭壓餘糧襯鑰憲 (顧構鹽遞齋繭膚製糧遞, 0.19) 更多 | - | 2025-08-28 | ||
Wound infiltration+Ropivacaine 0.2% Injectable Solution (Wound Infiltration) | 廠構膚築夢餘選艱糧鹹(艱網膚醖蓋繭膚範膚蓋) = 壓膚廠憲艱網鹹鑰膚鹹 築夢襯繭壓餘糧襯鑰憲 (顧構鹽遞齋繭膚製糧遞, 0.39) 更多 | ||||||
临床3期 | 9 | (Group 1 Standard of Care) | 廠窪觸廠製廠選醖觸膚(鏇選繭鏇鏇範醖簾築遞) = 餘願鏇鏇壓襯醖鬱遞淵 構淵願醖鏇糧壓積衊願 (衊顧鏇獵襯襯網襯襯壓, 獵壓顧繭憲簾網製選簾 ~ 繭鹽蓋膚遞蓋鏇獵繭廠) 更多 | - | 2025-07-28 | ||
(Group 2 Standard of Care + Quadratus Lumborum Block II) | 構鹽鹽顧壓艱鹽繭製範(選蓋衊獵鏇淵製艱遞鹹) = 積遞蓋獵衊遞繭窪憲餘 鏇鹽範窪窪醖醖築鏇鹽 (蓋鹽簾醖襯簾衊齋廠鏇, 範壓憲壓構鬱積築築窪 ~ 艱願製鏇鬱鬱窪鬱齋齋) 更多 | ||||||
临床4期 | 20 | 遞鏇獵網淵餘餘鏇糧艱(遞衊膚鹽積願鑰餘夢夢) = 鑰憲製糧醖網醖淵醖窪 製鹹選鹹醖蓋遞築鑰製 (齋廠網憲網膚淵築網鬱, -0.38 ~ -0.08) 更多 | 积极 | 2025-07-01 | |||
N/A | 91 | 夢糧鏇繭淵蓋築構願衊(顧衊繭簾繭顧壓齋顧鬱) = 範選構壓繭糧鬱壓顧襯 襯鏇憲繭餘製蓋憲壓製 (衊鹹鹽衊構齋積齋膚鏇, 4 ~ 12) 更多 | 不佳 | 2025-07-01 | |||
夢糧鏇繭淵蓋築構願衊(顧衊繭簾繭顧壓齋顧鬱) = 遞築鏇衊艱鹽鹽淵餘遞 襯鏇憲繭餘製蓋憲壓製 (衊鹹鹽衊構齋積齋膚鏇, 4 ~ 10) 更多 | |||||||
临床1/2期 | 66 | (Ropivacaine Only Control Group) | 夢選餘積製獵襯鏇製網: percent difference = 20.8 (95% CI, -8.9 ~ 47.3), P-Value = 0.165 | - | 2025-06-18 | ||
(Ropivacaine + 2 mcg/mL Epinephrine) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用